ID   DF15R
AC   CVCL_Y430
DR   Wikidata; Q54831024
RX   PubMed=22552008;
CC   Selected for resistance to: ChEBI; CHEBI_72690; Pomalidomide (3-amino-thalidomide; CC-4047).
CC   Cell type: B-cell; CL=CL_0000236.
DI   NCIt; C3242; Plasma cell myeloma
DI   ORDO; Orphanet_29073; Multiple myeloma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_Y429 ! DF15
SX   Sex unspecified
AG   Age unspecified
CA   Cancer cell line
DT   Created: 07-11-14; Last updated: 19-12-24; Version: 7
//
RX   PubMed=22552008; DOI=10.1038/leu.2012.119; PMCID=PMC3496085;
RA   Lopez-Girona A., Mendy D., Ito T., Miller K., Gandhi A.K., Kang J.,
RA   Karasawa S., Carmel G., Jackson P., Abbasian M., Mahmoudi A.,
RA   Cathers B., Rychak E., Gaidarova S., Chen R., Schafer P.H., Handa H.,
RA   Daniel T.O., Evans J.F., Chopra R.;
RT   "Cereblon is a direct protein target for immunomodulatory and
RT   antiproliferative activities of lenalidomide and pomalidomide.";
RL   Leukemia 26:2326-2335(2012).
//